FY2025 Earnings Estimate for BMY Issued By Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings per share (EPS) estimate for Bristol Myers Squibb to $6.52, increasing from a prior forecast of $6.28, although this is below the consensus estimate of $6.74.
• Bristol Myers Squibb recently reported a quarterly EPS of $1.46, significantly beating analyst predictions of $1.07, with revenue reaching $12.27 billion, above estimates of $11.32 billion.
• The company has declared a quarterly dividend of $0.62 per share, representing an annual yield of 5.2%, with a payout ratio of 100%.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Investment analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for Bristol Myers Squibb in a research note issued to investors on Wednesday, August 13th. Cantor Fitzgerald analyst C. Gould now expects that the biopharmaceutical company will post earnings of $6.52 per share for the year, up from their prior forecast of $6.28. Cantor Fitzgerald has a "Neutral" rating and a $55.00 price objective on the stock. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share.

Several other analysts have also recently weighed in on the company. Daiwa Capital Markets cut Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price target for the company. in a report on Tuesday, August 5th. Wall Street Zen cut Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. William Blair reissued a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Citigroup decreased their price target on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research note on Friday, August 1st. Finally, Jefferies Financial Group lowered their price target on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $56.38.

Bristol Myers Squibb Stock Performance

Shares of NYSE:BMY traded down $0.25 during trading on Friday, reaching $48.19. 7,865,214 shares of the stock were exchanged, compared to its average volume of 12,742,200. Bristol Myers Squibb has a 12 month low of $42.96 and a 12 month high of $63.33. The stock has a 50-day moving average price of $47.21 and a 200-day moving average price of $51.32. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The firm has a market cap of $98.09 billion, a PE ratio of 19.43, a PEG ratio of 2.48 and a beta of 0.36.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.27 billion during the quarter, compared to analysts' expectations of $11.32 billion. During the same quarter last year, the company posted $2.07 EPS. Bristol Myers Squibb's quarterly revenue was up .6% compared to the same quarter last year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Marcum Wealth LLC increased its stake in shares of Bristol Myers Squibb by 1.0% in the 1st quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company's stock valued at $1,177,000 after purchasing an additional 193 shares during the last quarter. Beacon Investment Advisory Services Inc. boosted its stake in Bristol Myers Squibb by 2.7% in the first quarter. Beacon Investment Advisory Services Inc. now owns 8,063 shares of the biopharmaceutical company's stock valued at $492,000 after buying an additional 212 shares in the last quarter. Exchange Capital Management Inc. boosted its stake in Bristol Myers Squibb by 0.4% in the second quarter. Exchange Capital Management Inc. now owns 54,893 shares of the biopharmaceutical company's stock valued at $2,541,000 after buying an additional 220 shares in the last quarter. 1858 Wealth Management LLC grew its position in Bristol Myers Squibb by 3.6% in the first quarter. 1858 Wealth Management LLC now owns 6,421 shares of the biopharmaceutical company's stock valued at $392,000 after acquiring an additional 221 shares during the last quarter. Finally, Parsons Capital Management Inc. RI raised its stake in Bristol Myers Squibb by 0.3% during the second quarter. Parsons Capital Management Inc. RI now owns 78,105 shares of the biopharmaceutical company's stock worth $3,615,000 after acquiring an additional 224 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Thursday, July 3rd were paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.1%. The ex-dividend date of this dividend was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is 100.00%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.